Crescita Therapeutics Inc.
CRRTF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.59 | -0.01 | -0.01 | 0.23 |
| FCF Yield | 12.62% | -2.83% | -5.42% | 8.22% |
| EV / EBITDA | 0.97 | -1.27 | -5.04 | 19.63 |
| Quality | ||||
| ROIC | -0.96% | 3.58% | -6.78% | -1.47% |
| Gross Margin | 52.94% | 61.37% | 49.39% | 43.39% |
| Cash Conversion Ratio | 1.56 | -0.00 | 0.55 | -8.49 |
| Growth | ||||
| Revenue 3-Year CAGR | 5.43% | -2.44% | -7.87% | -5.94% |
| Free Cash Flow Growth | 751.45% | 70.12% | -156.60% | 350.74% |
| Safety | ||||
| Net Debt / EBITDA | -6.82 | -6.52 | 13.79 | -41.37 |
| Interest Coverage | -16.20 | 48.58 | -88.50 | -17.87 |
| Efficiency | ||||
| Inventory Turnover | 0.47 | 0.49 | 0.35 | 0.96 |
| Cash Conversion Cycle | 222.07 | 9.75 | -8.04 | -1.13 |